Early Experience of Oncolytic Virus Injection Combined with Sorafenib in a Patient with Advanced Hepatocellular Carcinoma and Portal Vein Thrombosis

JX-594 is a modified oncolytic poxvirus designed to selectively replicate in and destroy cancer cells. In a pilot study, JX-594 injection followed by sorafenib was well-tolerated in three patients and associated with objective tumor responses. In this study, we report a case in which a patient with...

Descripción completa

Detalles Bibliográficos
Autores principales: Jo, Hyun Ho, Chun, Seong Joon, Yoo, Jeong-Ju, Lee, Min Hee, Kim, Sang Gyune, Kim, Young Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Liver Cancer Association 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035676/
https://www.ncbi.nlm.nih.gov/pubmed/37384323
http://dx.doi.org/10.17998/jlc.20.2.177
Descripción
Sumario:JX-594 is a modified oncolytic poxvirus designed to selectively replicate in and destroy cancer cells. In a pilot study, JX-594 injection followed by sorafenib was well-tolerated in three patients and associated with objective tumor responses. In this study, we report a case in which a patient with advanced hepatocellular carcinoma and portal vein thrombosis was treated with a combination of JX-594 and sorafenib.

Ejemplares similares